Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients.
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer took place in Seattle, Washington, March 14-17. This global gathering of experts on gynecologic cancers had access to educational programs, scientific plenaries, focused forums, and posters and abstracts centered around the latest data on treatment advancements. Among the late-breaking abstracts on endometrial cancer were the findings of the DUO-E trial, which examined the mismatch repair–proficient subpopulation receiving durvalumab with or without olaparib as maintenance therapy. Other key studies included a phase 1/2a safety and preliminary efficacy study of the novel antibody-drug conjugate puxitatug samrotecan, and data from the phase 2 RESOLVE study evaluating the combination of metformin, letrozole, and abemaciclib for recurrent endometrial cancer. Additionally, the PUMBA study revealed disparities in care, showing that Black patients with postmenopausal bleeding were less likely to receive timely endometrial sampling after an abnormal ultrasound, increasing the risk for later-stage diagnoses.
Kathleen N. Moore, MD, MS
Deputy Director, Department of Gynecologic Oncology, Stephenson Cancer Center, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
“It [this meeting] did, I believe, reinvigorate the kind of clinical equipoise around investigating how to best individualize therapies for patients with endometrial cancer, especially those whose tumors are deemed nondeficient mismatch repair.”
Preconference Considerations
SGO 2025: Previewing Advancements in Endometrial Cancer
Dr Moore discusses recent advancements in endometrial cancer in looking ahead to SGO 2025, particularly the use of immune checkpoint inhibitors with chemotherapy. She is excited to see further data on survival rates, especially in patients with deficient mismatch repair (dMMR), and the potential role of antibody-drug conjugates in treatment. Dr Moore also looks forward to ongoing research on personalized therapies, including endocrine treatments, and hopes to see more progress in molecular subtypes beyond dMMR.
Quick Clinical Takeaways
SGO 2025: Gaining Ground in Endometrial Cancer
Dr Moore delineates exciting developments in endometrial cancer treatment presented at SGO 2025. The DUO-E trial highlighted the addition of durvalumab and olaparib to chemotherapy for metastatic endometrial cancer, showing promising progression-free survival (PFS) and high ctDNA detection rates. Puxitatug samrotecan, an antibody-drug conjugate targeting B7-H4, demonstrated a 35%-38% response rate and 7 months of PFS in recurrent endometrial cancer. Additionally, a phase 2 study of letrozole, abemaciclib, and metformin showed a 32% response rate, with notable efficacy in tumors without RB1 loss or cyclin E amplification.
How Will My Patients Benefit?
SGO 2025: Impact of Precision Medicine in Endometrial Cancer
Dr Moore describes how the 2025 Society of Gynecologic Oncology Annual Meeting highlighted the need for individualized therapies in endometrial cancer, particularly for patients with nondeficient mismatch repair tumors, which are molecularly heterogeneous. Key presentations, such as Dr Debra Richardson’s on the SIENDO study, showcased the potential benefit of selinexor maintenance therapy in TP53 wild-type populations, with ongoing trials like XPORT-EC-042 aimed at refining treatment options. The meeting emphasized the importance of careful molecular subgroup classification and validated biomarkers to guide future therapy decisions.
Polling Question
Summary
The 2025 Society of Gynecologic Oncology Annual Meeting highlighted key advancements in endometrial cancer treatment, emphasizing individualized therapies. Dr Kathleen Moore discussed promising findings, including the DUO-E trial’s success with durvalumab and olaparib; positive response rates for puxitatug samrotecan; and a phase 2 study showing efficacy for letrozole, abemaciclib, and metformin. Dr Debra Richardson’s presentation on the SIENDO study highlighted selinexor’s potential in TP53 wild-type populations, with ongoing trials refining treatment strategies. The meeting underscored the importance of molecular subgroup classification and validated biomarkers to guide future therapies.
Resources:
